Sorrento Therapeutics (NASDAQ:SRNE) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE) in a research report released on Monday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Sorrento Therapeutics Stock Performance

SRNE stock opened at $0.02 on Monday. The firm has a 50 day moving average of $0.02 and a 200-day moving average of $0.05. Sorrento Therapeutics has a 12-month low of $0.00 and a 12-month high of $0.42.

About Sorrento Therapeutics

Sorrento Therapeutics, Inc engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates.